Prevention
Find the latest research associated with preventative efforts to reduce the disease burden of COVID-19.Virus Inactivation
Passive and Induced Immunity
April 2021
- *NEW Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
- *NEW Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
- *NEW An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity.
- *NEW SARS-CoV-2 immune evasion by variant B.1.427/B.1.429.
- *NEW SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
- *NEW Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study.
March 2021
- Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient.
- B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies.
- T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals.
- Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naïve and Recovered Individuals Following mRNA Vaccination.
- Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection.
- Integrated immune dynamics define correlates of COVID-19 severity and antibody responses.
- Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike.
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
- Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
- Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations.
- SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.
- Research Tool SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.
- Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.
- Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19.
- Prolonged evolution of the human B cell response to SARS-CoV-2 infection.
- Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains.
- The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD.
- COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses.
- Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees.
- Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2.
February 2021
January 2021
2020
Back to TopVaccine Design and Development
April 2021
- *NEW Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
- *NEW Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents.
- *NEW SARS-CoV-2 mRNA vaccines induce a robust germinal center reaction in humans.
- *NEW Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study).
March 2021
- A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants.
- A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates.
- Design and proof-of-concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain.
- Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening.
- Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
- A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
- Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers - a Danish cohort study.
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
- Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2.
- Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
- Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
- Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals.
- Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
- Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern.
- SARS-CoV-2 seropositivity after infection and antibody response to mRNA-based vaccination.
- SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies.
- Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
- Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant.
- A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
- Decreased SARS-CoV-2 viral load following vaccination.